Isoschaftoside reverses nonalcoholic fatty liver disease via activating autophagy in vivo and in vitro

HIGHLIGHTS

• who: Yanze Su and colleagues from the Department of Clinical Medicine, Weifang Medical University, Weifang, China have published the Article: Isoschaftoside Reverses Nonalcoholic Fatty Liver Disease via Activating Autophagy In Vivo and In Vitro, in the Journal: Evidence-Based Complementary and Alternative Medicine of 27/06/2022
• what: The authors show that isoschaftoside (ISO) dramatically reduces lipid deposition in cells. The authors propose that ISO might alleviate hepatic steatosis in NAFLD via regulating autophagy machinery. The authors conducted a study with HepG2 cells. The study showed that ISO reduced PA-induced intracellular lipid droplets in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.